Stock vs Stock Comparison

Arcturus Therapeutics Holdings Inc. vs Johnson & Johnson

JNJ wins the Tale of the Tape 8–1.

ARCT$7.60
JNJ$223.24

🏆 Tale of the Tape

18
ARCTJNJ
-97.9%Profitability (Net Margin)28.5%
Valuation (P/E)26.1x
-22.1%Efficiency (ROIC)18.3%
1/9Health (Piotroski F)4/9
0.2Safety (Altman Z)4.0
-51.4%Growth (Rev YoY)6.0%
0.31Risk (Sharpe 1Y)2.69
0.27xBalance Sheet (D/E)1.44x
-1110.66%FCF Yield3.25%

Green = winner in each category. Higher is better except P/E (lower = cheaper).

Rolling Correlation

0.085
252-Day Correlation
0.115
126-Day Correlation

Low correlation — excellent diversification pair.

Fundamentals

MetricARCTJNJ
Market Cap$0.2B$542.4B
P/E Ratio26.1x
Forward P/E-2.0x17.7x
P/B1.18x6.68x
Dividend Yield2.38%
Beta2.420.26

Quantitative Metrics

MetricARCTJNJ
DCF Fair Value$134.24
DCF Upside-43.6%
Piotroski F1/94/9
Altman Z0.193.97
Beneish M-2.27
FCF Yield-1110.66%3.25%
Net Debt/EBITDA0.5x
ROIC-22.1%18.3%
WACC7.7%
ROIC – WACC10.5pp
Gross Margin67.9%
Net Margin-97.9%28.5%
Rev Growth YoY-51.4%6.0%
Sharpe (1Y)0.312.69
Max Drawdown 3Y-86.7%-16.0%
FCF Payout Ratio64%

ARCT Price

Loading chart...

JNJ Price

Loading chart...

ETF Exposure

ARCT found in:

VHT0.00%

JNJ found in:

XLV10.42%
IYH10.14%
VHT8.84%
HDV6.84%
MTUM3.76%
DIA2.83%
MGV2.75%
DGRO2.64%
VIG2.49%
VYM2.30%
VTV2.16%
DGRW2.02%
SCHV2.02%
IWD1.94%
QUS1.81%
XPH1.74%
VONV1.69%
NOBL1.58%
VFMV1.42%
VFMO1.02%
SCHX0.96%
SPYG0.94%
SDY0.93%
VOO0.90%
SCHB0.90%
SPY0.87%
IVV0.85%
VONE0.84%
SPTM0.81%
VTI0.80%
SPYV0.79%
SPLG0.76%
ITOT0.75%
URTH0.70%
ACWI0.57%
VT0.49%
RSP0.21%
VFVA0.15%
ONEO0.05%

More Comparisons

Quant metrics computed from financial statements and 1,200+ trading days. Correlation is Pearson coefficient on daily log returns. Not investment advice.

ARCT vs JNJ: Head-to-Head Analysis

Arcturus Therapeutics Holdings Inc. (ARCT) and Johnson & Johnson (JNJ) represent two companies in the Healthcare sector. In our quantitative Tale of the Tape scoring, JNJ leads 8–1 across nine fundamental and risk metrics including profitability, valuation, capital efficiency, and financial health.

In terms of capital efficiency, ARCT generates a return on invested capital (ROIC) of -22.1% compared to JNJ's 18.3%. This suggests JNJ is more effective at deploying capital to generate shareholder returns.

The 252-day rolling correlation between ARCT and JNJ is 0.085, indicating low correlation, making them an effective diversification pair in a portfolio context.

ARCT appears in 1 ETF tracked by SecuritiesDB, while JNJ appears in 39 ETFs. Investors holding broad-market ETFs may already have indirect exposure to both stocks.

Frequently Asked Questions

Which stock is the better investment, ARCT or JNJ?

Our quantitative analysis compares ARCT and JNJ across nine fundamental dimensions. JNJ wins the Tale of the Tape 8–1. However, stock selection depends on your individual risk tolerance, time horizon, and portfolio context. These metrics are computed from SEC filings and market data — they are not investment recommendations.

Are ARCT and JNJ correlated?

The 252-day correlation between ARCT and JNJ is 0.085. They have low correlation, offering good diversification.

How is the Tale of the Tape scored?

The Tale of the Tape compares both stocks across nine categories: profitability (net margin), valuation (P/E), efficiency (ROIC), health (Piotroski F-Score), safety (Altman Z-Score), growth (revenue YoY), risk (Sharpe ratio), leverage (debt-to-equity), and cash generation (FCF yield). The stock that wins more categories takes the overall score. Lower P/E and lower debt-to-equity count as wins.